Fc-Competent Fully Human Anti-TIGIT Blocking Monoclonal Antibodies Demonstrated Potent Anti-Tumor Efficacy in Preclinical Models
SUMMARY
We obtained novel, differentiating, fully human anti-TIGIT clones with the following properties and activities:
• High binding affinity
• Distinct epitopes from several clinical anti-TIGIT antibodies, including Tiragolumab•
• Potent blockade of hCD155 (hPVR) binding
• Capable of FcγIIIA-mediated signaling in reporter cells in IgG1 format
• Superior in vivo anti-tumor activity in syngeneic model
• Excellent stability under stressful conditions, making them good candidates for development
